Maryam Sadat Mirlohi

Dr. Maryam Sadat Mirlohi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MMMaryam Sadat Mirlohi
Maryam Sadat Mirlohi
HYHamid Yaghooti
Hamid Yaghooti
SSSaeed Shirali
Saeed Shirali
AAAli Aminasnafi
Ali Aminasnafi
SOSamaneh Olapour
Samaneh Olapour

24 November 2025 in Biomimetics
Verified
Journal Article
Open access
PDF file
MMMaryam Sadat Mirlohi
Maryam Sadat Mirlohi
TYTooba Yousefi
Tooba Yousefi
Amir ArefAmir Aref
Amir Aref
ASAmir Seyfoori
Amir Seyfoori
Traditional animal-based preclinical models, including xenografts and genetically engineered mice, have been used for assessing pharmacodynamics, toxicity, efficacy, and safety for decades. Despite their limited ability to mimic human tumor heterogeneity, immune interactions, and microenvironmental complexity, over 90% of oncology candidates that succeed in animal studies fail in clinical trials. The New Approach Methodologies (NAMs), which include patient-derived organoids, organ-on-chip platforms, and AI-driven computational models, provide human-relevant solutions that can improve predictive validity, mechanistic insight, and ethics. Through these technologies, it will be possible to replicate tumor biology specific to patients, to support co-clinical trial designs, and to facilitate biomarker discovery while reducing animal testing. Several recent regulatory reforms, including the Food and Drug Administration (FDA) Modernization Act 2.0 and the European Medicines Agency’s NAM qualification framework, have established clear pathways for the integration of validated NAMs into preclinical drug evaluation. Critically evaluating the scientific rationale, comparative performance, and regulatory context of key NAM platforms in oncology, this review highlights opportunities for synergistic integration, technical refinement, and global harmonization in order to accelerate the development of clinically effective cancer therapeutics based on preclinical findings.

17 March 2026 in Biofabrication
Verified
Journal Article
Open access
MMMaryam Sadat Mirlohi
Maryam Sadat Mirlohi
EHErfan Hamdi
Erfan Hamdi
MKMohammad Hossein Karimi
Mohammad Hossein Karimi
SSSiamak Salami
Siamak Salami
Amir ArefAmir Aref
Amir Aref
Mohsen AkbariMohsen Akbari
Mohsen Akbari
The drug development process in cancer faces significant challenges due to high failure rates in translational studies despite promising in vitro results. Additionally, conventional animal models exhibit inherent limitations and ethical concerns, constraining their relevance to cancer studies. Recognizing the pivotal role of the tumor microenvironment (TME) on cancer development and treatment outcomes, recent advancements in 3D microfluidic devices and tumor-on-a-chip models enabled researchers to explore the TME with enhanced accuracy and reliability, yielding novel insights. Notably, the emergence of physiological tumor models, particularly 3D models such as organoids derived from human tissues, provides a more accurate representation of in vivo tumor features. Moreover, 3D tumor models hold promise for diverse applications, including high-throughput drug testing, disease modeling, and regenerative medicine. Meanwhile, combining artificial intelligence (AI) with patient-derived tumor organoids has become a key strategy in predictive oncology and personalized cancer treatment. Furthermore, incorporating quantitative systems pharmacology and physiologically based pharmacokinetic modeling, and pharmacokinetics/pharmacodynamics analysis with generative AI (Gen-AI) has revolutionized predictive oncology by enabling precise simulations of drug interactions and patient-specific responses, thereby enhancing the predictive accuracy of personalized cancer treatments. These advanced methodologies harness the power of AI algorithms to analyze intricate datasets derived from patient-specific tumor organoids. Moreover, the predictive modeling capabilities of Gen-AI facilitate the development of personalized treatment strategies customized for each patient, thereby revolutionizing oncology practice. This review explores the synergistic impact of tumor-on-a-chip models, organoids derived from patient tumors, and Gen-AI. Together, these technologies mark a significant advancement in precision medicine, offering promising opportunities to improve therapeutic effectiveness and treatment outcomes in cancer care.

22 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MMMaryam Sadat Mirlohi
Maryam Sadat Mirlohi
TYTooba Yousefi
Tooba Yousefi
JRJavad Razaviyan
Javad Razaviyan
SNSamira Nomiri
Samira Nomiri
EPEsmail Pishbin
Esmail Pishbin
SSSiamak Salami
Siamak Salami
Aberrant activation of the RAS signaling pathway is a halmark of various cancers. This activation, is often caused by mutations in RAS genes or other pathway components and, drivesi uncontrolled cell growth and proliferation. Studies have demonstrated that certain codon mutations can significantly influence the clinical outcomes of cancer patients. Historically, KRAS was considered “undruggable”; however, recent advancements in drug discovery have led to the development of promising KRAS inhibitors. Accurately identifying the specific type of KRAS mutation in a patient is essential for making optimal treatment decisions. Several methods have been developed for detecting KRAS mutations to address this need, focusing on creating robust, rapid, sensitive, accurate, and cost-effective approaches, particularly for point-of-care applications. Starting with the Ras family and RASopathies, this review provides a comprehensive overview of KRAS mutation detection methods, ranging from research-use-only techniques to in vitro diagnostic-certified tests. Published results are critically evaluated in terms of accuracy, sensitivity, cost, throughput, and suitability for various sample types and clinical settings. This, offers researchers and clinicians an up-to-date resource for.

20 February 2022 in Journal of Advanced Biomedical Sciences
Verified
Journal Article
Closed access
HYH Yaghooti
H Yaghooti
MMMaryam Sadat Mirlohi
Maryam Sadat Mirlohi
SSS Shirali
S Shirali
AAA AminAsnafi
A AminAsnafi
Background & Objective: Beta-thalassemia are among the most common autosomal recessive genetic disorders in Iran, especially in Khuzestan province. Beta-thalassemia exhibits significant phenotype heterogeneity and there are currently more than 200 known mutations in this region. Oxidative stress exacerbates multiple disorders, including thalassemia, an inherited hemolytic anemia caused by globin gene mutations. We aim to characterize significant mutations of widespread β-thalassemia in south-western Iran with respect to biochemical parameters, oxidative status and complications of diseases. Material & method: Forty-five patients, aged between 15-35 years with β-thalassemia major were selected. The patients were receiving regular blood transfusion and chelation therapy and have been previously characterized to bear beta globin gene mutations. The subjects’ medical histories were documented by review of previous medical records. We also determined biochemical parameters including glycemic and iron indices, hepatic and renal function tests, oxidative stress markers and levels of advanced glycation end product species (Carboxy methyl lysine and Pentosidin). Results: The most common mutation was found to be CD36/37(28.9%) followed by IVSII-1, and IVSI-110. Values of iron indices were significantly different in various mutation groups. Carboxy methyl lysine and pentosidine were found to be higher in the β-thalassemia patients with IVSII-1 and IVSI-110, respectively. Also sLOX-1 was found to be significantly higher in IVSI-110 group. Complications of the disease were differently presented in mutation groups and hemochromatosis, hepatomegaly, and diabetes were among the most common problems. Conclusion: About 72 % of β-thalassemia major cases in southwest Iran result form 3 common mutations with different clinical and laboratory presentations. Molecular genetic testing can be helpful to evaluate the patients’ situation.